NEW YORK (GenomeWeb) – Mediomics has received a $970,000 Small Business Innovation Research grant from the National Cancer Institute to develop a panel of single-chain variable fragments to detect modified proteins, the company said Friday.
The Phase II grant will fund Mediomics' efforts to use its Pincer platform to develop methods to screen for high-affinity monoclonal antibodies that can detect post-translation modification of proteins.
The St. Louis-based company provides assay kits, biosensors, and multiplexed assays for research use, point-of-care testing, and food and pharmaceutical production. The kits will be used to quantify macromolecules, including ligands, proteins, protein complexes, and a range of pathogens. The firm's homogenous assays have already been adapted for the detection of cAMP, tryptophan, S-adenosyl methionine, PDE, biotin, human insulin, and others.
In 2012, Mediomics received a $1 million SBIR grant from NCI to develop a bioanalyzer to detect the titer of protein drugs during their production, and a $740,000 SBIR grant from the Centers for Disease Control and Prevention to develop assays to detect HCV infection .
The company licensed its core technologies, including the Pincer-based bioassay platforms and devices, from St. Louis University.